Clean Science & Technology Ltd Q3 FY26 – 40% OPM, ₹300 Cr Capex, HALS Ramp-up vs 30% QoQ Profit Drop: Premium Chemistry or Cyclical Hangover?


1. At a Glance – The Lab Coat with a Gucci Belt

Let’s get this straight. Clean Science & Technology Ltd is not your random commodity chemical bhaiyya. This is a 40%+ OPM, near-zero debt, export-heavy, global rank-holder chemical nerd wearing a premium valuation suit.
Current price sits at ₹861, market cap ~₹9,150 Cr, ROCE 29%, ROE 21.9%, and then—plot twist—Q3 FY26 shows sales down ~20% YoY and profit down ~30% YoY.
So what’s happening? Is the chemistry broken or just digestion issues after a big HALS meal?

Performance Chemicals still rule the roost at ~69% of revenue, HALS has finally entered the chat, capex is peaking, China exposure is reducing, and promoters… well… they pressed the wrong sell button in Aug 2025.

This stock is behaving like a topper who suddenly scored 85 instead of 95. Still good, but parents are angry. Ready to dissect? 🧪


2. Introduction – From Darling to Doubt

Clean Science was once the poster child of “capital-efficient Indian specialty chemicals”.
IPO investors saw margins that made European peers jealous, a balance sheet cleaner than a pharma audit, and products where Clean was No.1 or No.2 globally.

Then came FY25–FY26:

  • China demand wobble
  • Inventory correction globally
  • HALS ramp-up pain
  • Promoter stake drama
  • And quarterly numbers that made Twitter analysts cry

But here’s the thing: this company still prints ~₹40 EBITDA on every ₹100 revenue. That doesn’t vanish overnight unless someone spills acid on the

plant floor.

So the real question is:
👉 Is this a structural slowdown… or just a cyclical chemistry hangover?


3. Business Model – WTF Do They Even Do?

Clean Science manufactures functionally critical specialty chemicals. Translation: chemicals that customers cannot easily replace without redesigning their entire process.

Three Buckets of Money:

1️⃣ Performance Chemicals (~69%)
MEHQ, BHA, AP, TBHQ, HALS
Used in polymers, food, cosmetics, oil, water treatment
Margins: Chef’s kiss 💋

2️⃣ Pharma & Agro Intermediates (~19%)
Guaiacol, DCC, Veratrole, DHDT
Used in APIs, cough syrups, anti-retrovirals
Regulatory moat + sticky customers

3️⃣ FMCG Chemicals (~12%)
4-MAP, Anisole
UV blockers, perfumes, pharma precursors
Mostly captive consumption = margin protection

The secret sauce? In-house R&D + backward integration + process chemistry.
They don’t sell tonnes. They sell precision.

Would you trust a random supplier for infant food antioxidants? Exactly.


4. Financials Overview – Numbers Don’t Lie, But They Do Smirk

📊 Quarterly Comparison (Standalone – ₹ Cr)

MetricLatest Qtr (Q3 FY26)YoY QtrPrev QtrYoY %QoQ %
Revenue185232213-19.9%-13.1%
EBITDA7210292-29.4%-21.7%
PAT527465-30.0%-20.0%
EPS (₹)4.886.976.08-30.0%-19.7%
To Read Full 16 Point ArticleBecome a member
Become a member
To Read Full 16 Point ArticleBecome a member

Leave a Comment

error: Content is protected !!